Evidence map›Paper›PMID 24777035›Full record

ArticleNature communications2014

Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

J-B Cazier, S R Rao, C M McLean, A K Walker, A L Walker, B J Wright, E E M Jaeger, C Kartsonaki, L Marsden, C Yau and 8 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Intravesical Delivery of P21 mRNA-Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. A five-gene mitochondria-associated prognostic signature for bladder cancer.International journal of clinical and experimental pathology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Deregulated Expression ofInternational journal of molecular sciences · 2023
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Walker, A L [corrected to Walker, A K]
5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

J-B Cazier1] Bioinformatics Group, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
S R Rao1] Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK [2] Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
C M McLean1] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Gray Institute for Radiobiology and Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
A K Walker
A L Walker1] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Gray Institute for Radiobiology and Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
B J WrightBioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
E E M JaegerMolecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
C KartsonakiBioinformatics Group, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
L Marsden1] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
C YauYau Group, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
C CampsNIHR Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
P KaisakiNIHR Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
Oxford-Illumina WGS500 Consortium
J TaylorNIHR Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK.
J W CattoAcademic Urology Unit, University of Sheffield, Sheffield S10 2JF, UK.
I P M Tomlinson1] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK [3] NIHR Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK [4].
A E Kiltie1] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Gray Institute for Radiobiology and Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [3].
F C Hamdy1] Cancer Research UK, Oxford Cancer Research Centre, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [2] Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK [3].
Centre for Human Genetics · GBUniversity of Oxford · GBIllumina (United Kingdom) · GBCancer Research UK Oxford Centre · GBImperial College London · GBJohn Radcliffe Hospital · GBOxford BioMedica (United Kingdom) · GBUniversity of Sheffield · GB

Funding

Biotechnology and Biological Sciences Research Council BB/I02593X/1Cancer Research UK 16459Medical Research Council MC_UU_12010/6Medical Research Council MR/L001411/1Wellcome Trust 084818Wellcome Trust 090532Wellcome Trust 090532/Z/09/Z
6 · The paper itself

Abstract

Bladder cancers are a leading cause of death from malignancy. Molecular markers might predict disease progression and behaviour more accurately than the available prognostic factors. Here we use whole-genome sequencing to identify somatic mutations and chromosomal changes in 14 bladder cancers of different grades and stages. As well as detecting the known bladder cancer driver mutations, we report the identification of recurrent protein-inactivating mutations in CDKN1A and FAT1. The former are not mutually exclusive with TP53 mutations or MDM2 amplification, showing that CDKN1A dysfunction is not simply an alternative mechanism for p53 pathway inactivation. We find strong positive associations between higher tumour stage/grade and greater clonal diversity, the number of somatic mutations and the burden of copy number changes. In principle, the identification of sub-clones with greater diversity and/or mutation burden within early-stage or low-grade tumours could identify lesions with a high risk of invasive progression.

Indexed as

Genetic VariationBase SequenceCadherinsCyclin-Dependent Kinase Inhibitor p21GenomeHumansMolecular Sequence DataMutationNeoplasm GradingSequence Analysis, DNAUrinary Bladder NeoplasmsCadherinsCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21FAT1 protein, human

Identifiers

PMID24777035
PMCPMC4010643
OpenAlexW1993583543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.